Drugs like trastuzumab (which targets HER2) are typically given for 12 months postsurgery for HER2‐positive breast cancer, but a recent trial showed that 6‐month treatment was noninferior to 12 months but was associated with less cardiotoxicity and fewer severe adverse events [8]. This evidence concerns the gene ERBB2 and breast cancer.